Regeneron Pharmaceuticals, Inc.

Julie Horowitz

Aris I Baras

Manuel Allen Revez Ferreira

Gavin Thurston

Luca Andrea Lotta

Goncalo Abecasis

Charles Paulding

Garen Manvelian

Eric Jorgenson

Amy Damask

Xinyuan Zhang

Stefan Semrau

Michael Cantor

Claudia G Gonzaga-Jauregui

The present disclosure provides methods of treating subjects having sepsis, SIRS, septic shock, and/or MODS, methods of identifying subjects having an increased risk of developing sepsis, SIRS, septic shock, and/or MODS, and methods of detecting Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and/or Low Density Lipoprotein Receptor (LDLR) variant nucleic acid molecules and variant polypeptides.

Treatment of sepsis with PCSK9 and LDLR modulators

The present disclosure provides methods of treating a subject having skin cancer or preventing a subject from developing skin cancer, and methods of identifying subjects having an increased risk of developing skin cancer.

Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors

Methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC) are provided herein.

Macrophage stimulating 1 receptor (MST1R) variants and uses thereof

Growing community of inventors

Tarrytown, NY, United States of America

Julie Horowitz